92
Participants
Start Date
August 29, 2024
Primary Completion Date
August 31, 2025
Study Completion Date
August 31, 2026
UGN-103
UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
RECRUITING
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RECRUITING
Crystal Run Healthcare, Middletown
RECRUITING
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, New York
RECRUITING
AccuMed Research Associates, Garden City
RECRUITING
Great Lakes Physician dba WNYU, Cheektowaga
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Peachtree Clinical Solutions, Powder Springs
RECRUITING
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
RECRUITING
Houston Metro Urology (HMU) - Southwest Location, Houston
RECRUITING
Houston Methodist Hospital, Houston
RECRUITING
Genesis Research, LLC, San Diego
RECRUITING
Spokane Urology, P.S., Spokane
RECRUITING
Garden State Urology, Morristown
RECRUITING
Urology Associates P.C. - Nashville, Nashville
UroGen Pharma Ltd.
INDUSTRY